// App-Quantinova.ai

TCT-331 : Multi-Center, Post-marketing Evaluation of the Elixir DESolve® Novolimus Eluting Bioresorbable Coronary Stent System: 24-month Results from the DESolve PMCF Study

Researchers

Presenter

  • Holger Nef

Principal Investigators

  • Azeem Latib

  • Lynn Morrison

  • Sara Toyloy

  • Lynn Vandertie

  • Antonio Colombo

Medical Centers

  • Elixir Medical, sunnyvale, California, United States

  • Medical Devices Consultancy, Christchurch, New Zealand

  • San Raffaele Scientific Institute, Milan, Italy

  • University of Giessen, Giessen, Germany

  • Interventional Cardiology Institute San Raffaele Hospital, Milan, Italy

Locations

  • United States

  • Italy

  • New Zealand

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Genetic Disorder

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

Disease

  • Stable coronary artery disease

  • Coronary artery lesions

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved